Month: March 2024

Telesat Reports Results for the Quarter and Twelve Months Ended December 31, 2023

Written by Customer Service on March 28, 2024. Posted in Earnings Releases And Operating Results.

OTTAWA, March 28, 2024 (GLOBE NEWSWIRE) — Telesat (NASDAQ and TSX: TSAT), one of the world’s largest and most innovative satellite operators, today announced its financial results for the three-month and one-year periods ended December 31, 2023. All amounts are in Canadian dollars and reported under International Financial Reporting Standards (IFRS) unless otherwise noted. “Telesat achieved a great deal in 2023 and I am pleased with our financial performance and, more importantly in terms of our future, the breakthrough we had in moving Telesat Lightspeed, our advanced Low Earth Orbit (LEO) satellite program, forward,” commented Dan Goldberg, Telesat’s President and CEO. “Our financial results reflect our continued disciplined execution, delivering Adjusted EBITDA1 above our 2023 guidance as well as industry-leading Adjusted EBITDA...

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Written by Customer Service on March 28, 2024. Posted in Earnings Releases And Operating Results.

Continued clinical and regulatory progress for the vebreltinib (APL-101) registration-enabling program Completed patient enrollment for the uproleselan (APL-106) Phase 3 bridging study in China – topline data expected in the first half of 2025 $37.8 million in cash, cash equivalents and money market funds as of December 31, 2023, with a cash runway through first quarter 2025 Management to host conference call today, Thursday, March 28, 2024 at 8:30 a.m. ETFOSTER CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) — Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the full year ended December 31, 2023, and highlighted progress...

Aya Gold & Silver: Record 2023 Production, Revenue and Operating Cash Flow

Written by Customer Service on March 28, 2024. Posted in Earnings Releases And Operating Results.

Announces 2024 GuidanceFigure 1 – Ongoing Installation of the Ball MillOngoing Installation of the Ball MillMONTREAL, March 28, 2024 (GLOBE NEWSWIRE) — Aya Gold & Silver Inc. (TSX: AYA, OTCQX: AYASF) (“Aya” or the “Corporation”) is pleased to announce financial and operational results for the fourth quarter and year ended December 31, 2023. All amounts are in US dollars, unless otherwise stated. Annual HighlightsExceeded 2023 production guidance with silver production of 1.97 million ounces (“oz”), a 5% increase from 2022. Ore processed of 281,634 tonnes (“t”) in 2023, a 10% increase from 254,976t in 2022. 493,340t of ore mined in 2023 for an average of 1,352 tonnes per day (“tpd”), a 79% increase from ore mined in 2022. Revenue of $42.8 million in 2023, a 12% increase from 2022. Beat 2023 cash cost guidance...

Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments

Written by Customer Service on March 28, 2024. Posted in Earnings Releases And Operating Results.

WILMETTE, Ill., March 28, 2024 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced fourth quarter and full-year 2023 financial results and summarized recent developments. Recent Developments Novel MNPR-101 Radiopharmaceutical Program targeting uPAR – Phase 1 dosimetry clinical trial to commence in the coming weeksMNPR-101-Zr Phase 1 dosimetry clinical trial has Human Research Ethics Committee (HREC) clearance in Australia and is on track to initiate at the Melbourne Theranostic Innovation Centre (MTIC) within the next few weeks.Will enroll patients with advanced cancers, aiming for those most likely to have uPAR expression, which include a majority of all triple-negative breast, colorectal, and...

Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Written by Customer Service on March 28, 2024. Posted in Earnings Releases And Operating Results.

–-Resubmission of NDA On Track for Early Q2 24— –-Cash Runway into 2025, including through Potential FDA Approval in Early Q4 24– –Company to host conference call today at 8:30amET– DUBLIN, Ireland and CHICAGO, March 28, 2024 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the fourth quarter and year ended December 31, 2023. “Since we announced positive topline data from our REASSURE trial in January, we’ve made significant progress in completing the new drug application (NDA) for the planned resubmission early in the second quarter,” said Corey Fishman,...

Stran & Company Reports 28.7% Increase in Sales and Achieves Profitability for the 2023 Fiscal Year

Written by Customer Service on March 28, 2024. Posted in Earnings Releases And Operating Results.

Benefitting from Increased Operating Efficiency and Economies of Scale, Evidenced by 156% Year-Over-Year Increase in Operating Income for the Fourth Quarter of 2023 Reports Net Earnings of $883,000 for the Fourth Quarter of 2023 Conference call to be held today at 10:00 AM ET QUINCY, Mass., March 28, 2024 (GLOBE NEWSWIRE) — Stran & Company, Inc. (“Stran” or the “Company”) (NASDAQ: SWAG) (NASDAQ: SWAGW), a leading outsourced marketing solutions provider that leverages its promotional products and loyalty incentive expertise, today provided a business update and reported financial results for the year ended December 31, 2023. Andy Shape, President and CEO of Stran, commented, “We made meaningful progress throughout 2023, resulting in record sales of approximately $75.9 million, a 28.7% increase over the...

Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates

Written by Customer Service on March 28, 2024. Posted in Earnings Releases And Operating Results.

Company continues to evaluate strategic options to maximize shareholder value MALVERN, Pa., March 28, 2024 (GLOBE NEWSWIRE) — Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the fourth quarter and year ended December 31, 2023 and provided recent corporate updates. “As a result of last year’s FDA request for a second Phase 3 trial to support the avasopasem NDA, we have implemented key measures to extend our cash runway and assess strategic alternatives,” said Mel Sorensen, M.D., Galera’s President and CEO. “Among these measures, we recognize that the decision to discontinue our GRECO trials was challenging for our team and our clinical...

AGF Investments Announces Proposed Termination of AGF Global Opportunities Bond ETF, AGF Systematic Canadian Equity ETF and AGF Systematic Emerging Markets Equity ETF

Written by Customer Service on March 28, 2024. Posted in Public Companies.

TORONTO, March 28, 2024 (GLOBE NEWSWIRE) — AGF Investments Inc. (AGF Investments) (TSX:AGF.B) today announced the proposed termination of AGF Global Opportunities Bond ETF (ticker: AGLB), AGF Systematic Canadian Equity ETF (ticker: QCD) and AGF Systematic Emerging Markets Equity ETF (ticker: QEM) (each an “AGF Investments ETF” and collectively, the “AGF Investments ETFs”) effective at the close of business on or about May 28, 2024 (the “ETF Termination Date”). Accordingly, AGF Investments will also request to de-list the units of the AGF Investments ETFs from the Toronto Stock Exchange (TSX) and Cboe Canada Inc. at the close of business on or about May 28, 2024 (the “Delisting Date”), with all units still held by securityholders being subject to a mandatory redemption as of the ETF Termination Date. Securityholders of the AGF Investments...

Affimed Reports 2023 Financial Results and Operational Progress

Written by Customer Service on March 28, 2024. Posted in Earnings Releases And Operating Results.

AFM24 combination with atezolizumab (AFM24-102): Follow-up of the Phase 1/2a combination study confirmed four responses in the non-small cell cancer (NSCLC) EGFR-wildtype cohort: one complete response (CR), three partial responses (PR), and seven stable disease patients in the 15 heavily pretreated patients who were evaluated. Mature progression free survival (PFS) data from the 15 EGFR-wildtype NSCLC patients and initial efficacy data from the EGFR-mutant NSCLC cohorts are expected in Q2 2024. Acimtamig (AFM13) combination with AlloNK® (AB-101) natural killer (NK) cells (LuminICE-203): Company on track to report initial efficacy and safety data in Q2 2024. AFM28: Currently enrolling patients in the sixth and final cohort of the Phase 1 dose-escalation study in patients with CD123-positive relapsed/refractory (r/r) AML. Restructuring...

Verde Announces Q4 and FY 2023 Results

Written by Customer Service on March 28, 2024. Posted in Earnings Releases And Operating Results.

(All figures are in Canadian dollars, unless stated otherwise. Average exchange rate in FY 2023: C$1.00 = R$3.70) SINGAPORE, March 28, 2024 (GLOBE NEWSWIRE) — Verde AgriTech Ltd (TSX: “NPK”) (“Verde” or the “Company”) announces its financial results for the full year ended December 31, 2023 (“FY 2023”) and the fourth quarter 2023 (“Q4 2023”), as audited by Ernst & Young (“EY”). The FY 2023 audited results were consistent with the interim results announced by the Company on January 26, 2024:Metric January 26, 2024 press release FY 2023 Audited resultsSales (tons) 4280,000 428,000Revenue (C$) 37.5 million – 38.5 million 37.9 millionEBITDA (C$) 1.5 million – 2.5 million 2.0 millionNet loss range (C$) 5.0 million – 6.0 million 6.0 millionCDR potential (tons of CO2) 17,680 17,680“Unfortunately,...

Month: March 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice